<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FDA Approval Process - Detailed Guide</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: white;
            display: flex;
            justify-content: center;
            align-items: center;
            min-height: 100vh;
            padding: 40px 20px;
        }
        
        .container {
            max-width: 960px;
            padding: 35px 45px;
            background: white;
        }
        
        .title {
            font-size: 28px;
            font-weight: 600;
            color: #1E64C8;
            margin-bottom: 25px;
            text-align: center;
        }
        
        .flowchart-section {
            background: #f8fbff;
            border: 2.5px solid #1E64C8;
            border-radius: 10px;
            padding: 20px;
            margin-bottom: 20px;
        }
        
        .flowchart-title {
            font-size: 18px;
            font-weight: 700;
            color: #1E64C8;
            text-align: center;
            margin-bottom: 15px;
        }
        
        .concept-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 18px;
            margin-bottom: 40px;
        }
        
        .concept-card {
            background: white;
            border: 2.5px solid #1E64C8;
            border-radius: 10px;
            padding: 16px;
            transition: all 0.3s;
            min-height: 100px;
        }
        
        .concept-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 6px 20px rgba(30, 100, 200, 0.2);
            background: #f8fbff;
        }
        
        .concept-name {
            font-size: 17px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 8px;
        }
        
        .concept-desc {
            font-size: 14px;
            color: #333;
            line-height: 1.5;
        }
        
        /* Detailed Section Styles */
        .detailed-section {
            margin-top: 50px;
            padding-top: 30px;
            border-top: 3px solid #1E64C8;
        }
        
        .section-title {
            font-size: 24px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 30px;
            text-align: center;
        }
        
        .detail-card {
            background: #f8fbff;
            border: 2.5px solid #1E64C8;
            border-radius: 12px;
            padding: 30px;
            margin-bottom: 40px;
            box-shadow: 0 4px 10px rgba(30, 100, 200, 0.1);
        }
        
        .detail-header {
            display: flex;
            align-items: center;
            margin-bottom: 20px;
            padding-bottom: 15px;
            border-bottom: 2px solid #1E64C8;
        }
        
        .detail-number {
            background: #1E64C8;
            color: white;
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 20px;
            font-weight: 700;
            margin-right: 15px;
            flex-shrink: 0;
        }
        
        .detail-title {
            font-size: 22px;
            font-weight: 700;
            color: #1E64C8;
        }
        
        .detail-content {
            margin-bottom: 25px;
        }
        
        .detail-subsection {
            margin-bottom: 20px;
        }
        
        .subsection-title {
            font-size: 16px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 10px;
            margin-top: 15px;
        }
        
        .detail-text {
            font-size: 14px;
            color: #333;
            line-height: 1.8;
            margin-bottom: 10px;
        }
        
        .detail-list {
            margin-left: 20px;
            margin-top: 10px;
        }
        
        .detail-list li {
            font-size: 14px;
            color: #333;
            line-height: 1.8;
            margin-bottom: 8px;
        }
        
        .example-box {
            background: white;
            border: 2px solid #90ee90;
            border-radius: 8px;
            padding: 20px;
            margin-top: 15px;
        }
        
        .example-title {
            font-size: 15px;
            font-weight: 700;
            color: #2d862d;
            margin-bottom: 10px;
            display: flex;
            align-items: center;
        }
        
        .example-icon {
            margin-right: 8px;
            font-size: 18px;
        }
        
        .example-text {
            font-size: 14px;
            color: #333;
            line-height: 1.7;
        }
        
        .visual-diagram {
            background: white;
            border: 2px solid #1E64C8;
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
            text-align: center;
        }
        
        .diagram-label {
            font-size: 13px;
            color: #666;
            margin-top: 10px;
            font-style: italic;
        }
        
        .key-points {
            background: #fff9e6;
            border-left: 4px solid #ffd700;
            padding: 15px 20px;
            margin-top: 15px;
            border-radius: 5px;
        }
        
        .key-points-title {
            font-size: 15px;
            font-weight: 700;
            color: #b8860b;
            margin-bottom: 10px;
        }
        
        .timeline-badge {
            display: inline-block;
            background: #e8f2ff;
            color: #1E64C8;
            padding: 5px 15px;
            border-radius: 20px;
            font-size: 13px;
            font-weight: 600;
            margin-top: 10px;
        }
        
        .risk-badge {
            display: inline-block;
            padding: 5px 12px;
            border-radius: 15px;
            font-size: 12px;
            font-weight: 600;
            margin-right: 8px;
        }
        
        .risk-low {
            background: #90ee90;
            color: #2d862d;
        }
        
        .risk-moderate {
            background: #ffd700;
            color: #b8860b;
        }
        
        .risk-high {
            background: #ffb3b3;
            color: #c41e3a;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="title">FDA Approval Process for AI/ML Medical Devices</div>
        
        <div class="flowchart-section">
            <div class="flowchart-title">Regulatory Pathways for AI/ML Medical Devices</div>
            <svg width="880" height="260" viewBox="0 0 880 260">
                <!-- Start -->
                <ellipse cx="440" cy="25" rx="80" ry="20" fill="#1E64C8" opacity="0.8"/>
                <text x="440" y="30" font-size="12" fill="white" font-weight="600" text-anchor="middle">New AI Device</text>
                
                <!-- Decision diamond -->
                <path d="M 440 55 L 520 100 L 440 145 L 360 100 Z" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                <text x="440" y="97" font-size="11" fill="#1E64C8" font-weight="600" text-anchor="middle">Predicate</text>
                <text x="440" y="110" font-size="11" fill="#1E64C8" font-weight="600" text-anchor="middle">exists?</text>
                
                <!-- Arrow down from start -->
                <path d="M 440 45 L 440 55" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrowhead)"/>
                
                <!-- YES path to 510(k) -->
                <path d="M 360 100 L 240 100" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrowhead)"/>
                <text x="300" y="93" font-size="10" fill="#1E64C8" font-weight="600">YES</text>
                
                <!-- 510(k) pathway -->
                <rect x="120" y="70" width="120" height="60" rx="8" fill="#b3d7ff" stroke="#1E64C8" stroke-width="2"/>
                <text x="180" y="92" font-size="13" fill="#1E64C8" font-weight="700" text-anchor="middle">510(k)</text>
                <text x="180" y="107" font-size="10" fill="#333" text-anchor="middle">Substantial</text>
                <text x="180" y="120" font-size="10" fill="#333" text-anchor="middle">Equivalence</text>
                
                <text x="180" y="150" font-size="9" fill="#666" text-anchor="middle" font-weight="600">‚è± 3-6 months</text>
                <rect x="155" y="155" width="50" height="12" rx="6" fill="#90ee90" opacity="0.6"/>
                <text x="180" y="164" font-size="8" fill="#333" font-weight="600" text-anchor="middle">FASTEST</text>
                
                <!-- NO path decision -->
                <path d="M 520 100 L 600 100" stroke="#1E64C8" stroke-width="2"/>
                <text x="560" y="93" font-size="10" fill="#1E64C8" font-weight="600">NO</text>
                
                <!-- Risk decision -->
                <path d="M 680 50 L 720 100 L 680 150 L 640 100 Z" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                <text x="680" y="97" font-size="11" fill="#1E64C8" font-weight="600" text-anchor="middle">High</text>
                <text x="680" y="110" font-size="11" fill="#1E64C8" font-weight="600" text-anchor="middle">Risk?</text>
                
                <path d="M 600 100 L 640 100" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrowhead)"/>
                
                <!-- De Novo (Low-Moderate Risk) -->
                <path d="M 680 50 L 680 20" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrowhead)"/>
                <text x="710" y="35" font-size="10" fill="#1E64C8" font-weight="600">NO</text>
                
                <rect x="600" y="0" width="160" height="20" rx="10" fill="#d4e7ff" stroke="#1E64C8" stroke-width="2"/>
                <text x="680" y="14" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">De Novo Classification</text>
                
                <g transform="translate(610, 25)">
                    <text x="70" y="0" font-size="9" fill="#333" text-anchor="middle">Novel low-moderate risk</text>
                    <text x="70" y="12" font-size="9" fill="#666" font-weight="600" text-anchor="middle">‚è± 6-12 months</text>
                </g>
                
                <!-- PMA (High Risk) -->
                <path d="M 680 150 L 680 180" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrowhead)"/>
                <text x="710" y="165" font-size="10" fill="#1E64C8" font-weight="600">YES</text>
                
                <rect x="600" y="180" width="160" height="60" rx="8" fill="#ffb3b3" opacity="0.4" stroke="#1E64C8" stroke-width="2"/>
                <text x="680" y="202" font-size="13" fill="#1E64C8" font-weight="700" text-anchor="middle">PMA</text>
                <text x="680" y="217" font-size="10" fill="#333" text-anchor="middle">Premarket Approval</text>
                <text x="680" y="230" font-size="9" fill="#333" text-anchor="middle">Clinical trials required</text>
                
                <text x="680" y="255" font-size="9" fill="#666" text-anchor="middle" font-weight="600">‚è± 12-18+ months</text>
                
                <!-- Post-market monitoring for all -->
                <rect x="90" y="190" width="200" height="50" rx="8" fill="#fff9e6" stroke="#1E64C8" stroke-width="2" stroke-dasharray="4,3"/>
                <text x="190" y="208" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">Post-Market Surveillance</text>
                <text x="190" y="223" font-size="9" fill="#333" text-anchor="middle">All pathways require continuous</text>
                <text x="190" y="235" font-size="9" fill="#333" text-anchor="middle">monitoring and reporting</text>
                
                <!-- Arrows to post-market -->
                <path d="M 180 130 L 180 190" stroke="#1E64C8" stroke-width="1.5" stroke-dasharray="3,2" marker-end="url(#arrowhead)"/>
                
                <!-- Legend -->
                <g transform="translate(20, 10)">
                    <text x="0" y="0" font-size="10" fill="#666" font-weight="600">Risk Level:</text>
                    <circle cx="0" cy="12" r="4" fill="#90ee90" opacity="0.6"/>
                    <text x="8" y="15" font-size="8" fill="#666">Class II (Low-Mod)</text>
                    <circle cx="0" cy="25" r="4" fill="#ffb3b3" opacity="0.6"/>
                    <text x="8" y="28" font-size="8" fill="#666">Class III (High)</text>
                </g>
                
                <defs>
                    <marker id="arrowhead" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                        <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                    </marker>
                </defs>
            </svg>
        </div>
        
        <div class="concept-grid">
            <div class="concept-card">
                <div class="concept-name">510(k) Pathway</div>
                <div class="concept-desc">Substantial equivalence to existing device. Fastest route, ~3-6 months if predicate exists</div>
            </div>
            
            <div class="concept-card">
                <div class="concept-name">De Novo Classification</div>
                <div class="concept-desc">Novel low-to-moderate risk devices. Creates new device category, ~6-12 months</div>
            </div>
            
            <div class="concept-card">
                <div class="concept-name">PMA Requirements</div>
                <div class="concept-desc">Premarket Approval for high-risk devices. Most rigorous, requires clinical trials</div>
            </div>
            
            <div class="concept-card">
                <div class="concept-name">Software Modifications</div>
                <div class="concept-desc">When algorithm changes require new submission. Predetermined change control plans</div>
            </div>
            
            <div class="concept-card">
                <div class="concept-name">Real-World Surveillance</div>
                <div class="concept-desc">Post-market monitoring. Detect performance drift or adverse events</div>
            </div>
        </div>

        <!-- DETAILED SECTIONS START HERE -->
        <div class="detailed-section">
            <div class="section-title">Detailed Regulatory Pathway Explanations</div>

            <!-- 1. 510(k) PATHWAY -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">1</div>
                    <div class="detail-title">510(k) Pathway - Substantial Equivalence</div>
                </div>
                
                <div class="detail-content">
                    <div class="timeline-badge">‚è± Timeline: 3-6 months</div>
                    <span class="risk-badge risk-low">Class II Device</span>
                    <span class="risk-badge risk-moderate">Moderate Risk</span>
                    
                    <div class="detail-subsection">
                        <div class="subsection-title">What is 510(k)?</div>
                        <p class="detail-text">
                            The 510(k) pathway allows medical device manufacturers to demonstrate that their new device is substantially equivalent to a legally marketed predicate device. This is the most common and fastest route to market for medical devices, including AI/ML-based diagnostic tools.
                        </p>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Key Requirements:</div>
                        <ul class="detail-list">
                            <li><strong>Predicate Device:</strong> Must identify an FDA-cleared device with similar intended use and technological characteristics</li>
                            <li><strong>Performance Testing:</strong> Demonstrate comparable safety and effectiveness through bench testing, software validation, and clinical performance data</li>
                            <li><strong>Labeling:</strong> Clear instructions for use, indications, contraindications, and warnings</li>
                            <li><strong>Software Documentation:</strong> Software design specification, risk analysis, validation and verification protocols</li>
                        </ul>
                    </div>

                    <div class="visual-diagram">
                        <svg width="800" height="120" viewBox="0 0 800 120">
                            <!-- Step 1 -->
                            <rect x="10" y="30" width="140" height="60" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="80" y="50" font-size="11" fill="#1E64C8" font-weight="700" text-anchor="middle">1. Identify</text>
                            <text x="80" y="65" font-size="10" fill="#333" text-anchor="middle">Predicate</text>
                            <text x="80" y="80" font-size="10" fill="#333" text-anchor="middle">Device</text>
                            
                            <!-- Arrow -->
                            <path d="M 150 60 L 170 60" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                            
                            <!-- Step 2 -->
                            <rect x="170" y="30" width="140" height="60" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="240" y="50" font-size="11" fill="#1E64C8" font-weight="700" text-anchor="middle">2. Performance</text>
                            <text x="240" y="65" font-size="10" fill="#333" text-anchor="middle">Testing &</text>
                            <text x="240" y="80" font-size="10" fill="#333" text-anchor="middle">Validation</text>
                            
                            <!-- Arrow -->
                            <path d="M 310 60 L 330 60" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                            
                            <!-- Step 3 -->
                            <rect x="330" y="30" width="140" height="60" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="400" y="50" font-size="11" fill="#1E64C8" font-weight="700" text-anchor="middle">3. Submit</text>
                            <text x="400" y="65" font-size="10" fill="#333" text-anchor="middle">510(k)</text>
                            <text x="400" y="80" font-size="10" fill="#333" text-anchor="middle">Application</text>
                            
                            <!-- Arrow -->
                            <path d="M 470 60 L 490 60" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                            
                            <!-- Step 4 -->
                            <rect x="490" y="30" width="140" height="60" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="560" y="50" font-size="11" fill="#1E64C8" font-weight="700" text-anchor="middle">4. FDA Review</text>
                            <text x="560" y="65" font-size="10" fill="#333" text-anchor="middle">3-6 months</text>
                            
                            <!-- Arrow -->
                            <path d="M 630 60 L 650 60" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                            
                            <!-- Step 5 -->
                            <rect x="650" y="30" width="140" height="60" rx="8" fill="#90ee90" opacity="0.6" stroke="#2d862d" stroke-width="2"/>
                            <text x="720" y="55" font-size="11" fill="#2d862d" font-weight="700" text-anchor="middle">5. Clearance</text>
                            <text x="720" y="75" font-size="10" fill="#333" text-anchor="middle">Market Ready</text>
                            
                            <defs>
                                <marker id="arrow2" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                    <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                                </marker>
                            </defs>
                        </svg>
                        <p class="diagram-label">510(k) Submission Process Flow</p>
                    </div>

                    <div class="example-box">
                        <div class="example-title">
                            <span class="example-icon">üí°</span>
                            Real-World Example: AI-Powered Diabetic Retinopathy Screening
                        </div>
                        <p class="example-text">
                            <strong>Device:</strong> IDx-DR (first FDA-authorized AI diagnostic system)<br><br>
                            <strong>Predicate:</strong> Traditional diabetic retinopathy screening methods and devices<br><br>
                            <strong>Substantial Equivalence:</strong> Demonstrated that the AI algorithm could detect diabetic retinopathy with sensitivity and specificity comparable to human experts. The device analyzes retinal images and provides a binary decision (referable diabetic retinopathy detected or not).<br><br>
                            <strong>Approval Timeline:</strong> Cleared through 510(k) process, allowing autonomous diagnostic decision-making at the point of care.
                        </p>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚úì Key Success Factors:</div>
                        <ul class="detail-list">
                            <li>Comprehensive predicate device comparison</li>
                            <li>Robust clinical validation data</li>
                            <li>Clear demonstration of equivalent safety profile</li>
                            <li>Well-documented software development lifecycle</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- 2. DE NOVO CLASSIFICATION -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">2</div>
                    <div class="detail-title">De Novo Classification - Novel Low-to-Moderate Risk Devices</div>
                </div>
                
                <div class="detail-content">
                    <div class="timeline-badge">‚è± Timeline: 6-12 months</div>
                    <span class="risk-badge risk-low">Class I/II Device</span>
                    <span class="risk-badge risk-moderate">Low-Moderate Risk</span>
                    
                    <div class="detail-subsection">
                        <div class="subsection-title">What is De Novo Classification?</div>
                        <p class="detail-text">
                            The De Novo pathway is designed for novel medical devices that are low-to-moderate risk but have no legally marketed predicate. This pathway creates a new device classification and can establish a predicate for future 510(k) submissions by other manufacturers. It's particularly relevant for innovative AI/ML technologies entering new clinical applications.
                        </p>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">When to Use De Novo:</div>
                        <ul class="detail-list">
                            <li><strong>Novel Technology:</strong> First-of-its-kind AI application with no existing predicate device</li>
                            <li><strong>New Intended Use:</strong> Device addresses a clinical need not previously covered by existing classifications</li>
                            <li><strong>Risk Assessment:</strong> Device presents low to moderate risk with appropriate special controls</li>
                            <li><strong>Innovation Pathway:</strong> Manufacturer wants to establish a new device category for future market entries</li>
                        </ul>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Special Controls Required:</div>
                        <ul class="detail-list">
                            <li>Clinical performance testing protocols</li>
                            <li>Software validation and cybersecurity measures</li>
                            <li>Training requirements for users</li>
                            <li>Post-market surveillance plans</li>
                            <li>Patient labeling and risk communication</li>
                        </ul>
                    </div>

                    <div class="visual-diagram">
                        <svg width="800" height="200" viewBox="0 0 800 200">
                            <!-- De Novo Process -->
                            <rect x="50" y="20" width="180" height="70" rx="8" fill="#d4e7ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="140" y="45" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">Novel Device</text>
                            <text x="140" y="62" font-size="10" fill="#333" text-anchor="middle">No Predicate</text>
                            <text x="140" y="78" font-size="10" fill="#333" text-anchor="middle">Low-Moderate Risk</text>
                            
                            <path d="M 230 55 L 270 55" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                            
                            <rect x="270" y="20" width="180" height="70" rx="8" fill="#fff9e6" stroke="#1E64C8" stroke-width="2"/>
                            <text x="360" y="40" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">Prepare De Novo</text>
                            <text x="360" y="57" font-size="9" fill="#333" text-anchor="middle">‚Ä¢ Risk Analysis</text>
                            <text x="360" y="70" font-size="9" fill="#333" text-anchor="middle">‚Ä¢ Special Controls</text>
                            <text x="360" y="83" font-size="9" fill="#333" text-anchor="middle">‚Ä¢ Clinical Data</text>
                            
                            <path d="M 450 55 L 490 55" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                            
                            <rect x="490" y="20" width="180" height="70" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="580" y="45" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">FDA Review</text>
                            <text x="580" y="62" font-size="10" fill="#333" text-anchor="middle">6-12 months</text>
                            <text x="580" y="78" font-size="10" fill="#333" text-anchor="middle">Classification Decision</text>
                            
                            <!-- Outcome branches -->
                            <path d="M 580 90 L 580 120" stroke="#1E64C8" stroke-width="2"/>
                            <path d="M 580 120 L 400 120" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                            <path d="M 580 120 L 670 120" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                            
                            <rect x="280" y="130" width="120" height="50" rx="8" fill="#90ee90" opacity="0.6" stroke="#2d862d" stroke-width="2"/>
                            <text x="340" y="150" font-size="11" fill="#2d862d" font-weight="700" text-anchor="middle">Granted</text>
                            <text x="340" y="165" font-size="9" fill="#333" text-anchor="middle">New Device</text>
                            <text x="340" y="177" font-size="9" fill="#333" text-anchor="middle">Classification</text>
                            
                            <rect x="670" y="130" width="120" height="50" rx="8" fill="#ffd700" opacity="0.4" stroke="#b8860b" stroke-width="2"/>
                            <text x="730" y="150" font-size="11" fill="#b8860b" font-weight="700" text-anchor="middle">Additional Info</text>
                            <text x="730" y="165" font-size="9" fill="#333" text-anchor="middle">More data</text>
                            <text x="730" y="177" font-size="9" fill="#333" text-anchor="middle">required</text>
                            
                            <defs>
                                <marker id="arrow3" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                    <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                                </marker>
                            </defs>
                        </svg>
                        <p class="diagram-label">De Novo Classification Process</p>
                    </div>

                    <div class="example-box">
                        <div class="example-title">
                            <span class="example-icon">üí°</span>
                            Real-World Example: Caption Guidance AI for Echocardiography
                        </div>
                        <p class="example-text">
                            <strong>Device:</strong> Caption Guidance - AI-powered ultrasound guidance system<br><br>
                            <strong>Innovation:</strong> First AI system to provide real-time guidance for capturing cardiac ultrasound images, helping non-expert users obtain diagnostic-quality images<br><br>
                            <strong>Why De Novo?:</strong> No existing predicate for AI-guided image acquisition assistance. The technology was novel but presented low-to-moderate risk with appropriate controls.<br><br>
                            <strong>Special Controls Established:</strong> Software validation requirements, user training protocols, image quality standards, and clinical performance benchmarks<br><br>
                            <strong>Impact:</strong> Created a new device classification (Class II), establishing a pathway for similar AI guidance technologies
                        </p>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚úì Advantages of De Novo:</div>
                        <ul class="detail-list">
                            <li>Establishes your device as the predicate for future 510(k) submissions</li>
                            <li>Provides competitive advantage as first-to-market in new category</li>
                            <li>Less burdensome than PMA while still addressing novel technology</li>
                            <li>Creates clear regulatory pathway for innovation</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- 3. PMA REQUIREMENTS -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">3</div>
                    <div class="detail-title">PMA (Premarket Approval) - High-Risk Devices</div>
                </div>
                
                <div class="detail-content">
                    <div class="timeline-badge">‚è± Timeline: 12-18+ months</div>
                    <span class="risk-badge risk-high">Class III Device</span>
                    <span class="risk-badge risk-high">High Risk</span>
                    
                    <div class="detail-subsection">
                        <div class="subsection-title">What is PMA?</div>
                        <p class="detail-text">
                            Premarket Approval (PMA) is the most stringent regulatory pathway, required for Class III devices that sustain or support life, prevent impairment of health, or present significant risk of illness or injury. PMA requires extensive clinical trials and scientific evidence to demonstrate reasonable assurance of safety and effectiveness.
                        </p>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">When PMA is Required:</div>
                        <ul class="detail-list">
                            <li><strong>Life-Sustaining Devices:</strong> AI systems that control life-critical functions (e.g., ventilator algorithms, cardiac monitoring)</li>
                            <li><strong>Implantable Devices:</strong> AI-enabled implantable devices or those directing implant functions</li>
                            <li><strong>Diagnostic Decisions:</strong> AI systems making autonomous diagnostic decisions for serious conditions without physician oversight</li>
                            <li><strong>Treatment Guidance:</strong> AI directing treatment interventions for high-risk conditions</li>
                        </ul>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Comprehensive Requirements:</div>
                        <ul class="detail-list">
                            <li><strong>Clinical Trials:</strong> Prospective, controlled clinical studies demonstrating safety and effectiveness</li>
                            <li><strong>Non-Clinical Testing:</strong> Extensive bench testing, animal studies, software validation</li>
                            <li><strong>Manufacturing Controls:</strong> Good Manufacturing Practice (GMP) compliance, quality systems</li>
                            <li><strong>Risk Analysis:</strong> Comprehensive failure mode analysis, hazard analysis</li>
                            <li><strong>Labeling:</strong> Detailed professional and patient labeling with risk disclosures</li>
                            <li><strong>Post-Approval Studies:</strong> Ongoing surveillance and additional studies may be required</li>
                        </ul>
                    </div>

                    <div class="visual-diagram">
                        <svg width="800" height="280" viewBox="0 0 800 280">
                            <!-- Phase 1: Pre-submission -->
                            <rect x="50" y="20" width="160" height="80" rx="8" fill="#ffb3b3" opacity="0.3" stroke="#c41e3a" stroke-width="2"/>
                            <text x="130" y="40" font-size="12" fill="#c41e3a" font-weight="700" text-anchor="middle">Phase 1</text>
                            <text x="130" y="56" font-size="10" fill="#333" text-anchor="middle">Pre-Submission</text>
                            <text x="130" y="70" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ FDA Meeting</text>
                            <text x="130" y="82" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ Protocol Agreement</text>
                            <text x="130" y="94" font-size="9" fill="#666" text-anchor="middle">2-4 months</text>
                            
                            <path d="M 210 60 L 240 60" stroke="#c41e3a" stroke-width="2" marker-end="url(#arrow4)"/>
                            
                            <!-- Phase 2: Clinical Trials -->
                            <rect x="240" y="20" width="160" height="80" rx="8" fill="#ffb3b3" opacity="0.3" stroke="#c41e3a" stroke-width="2"/>
                            <text x="320" y="40" font-size="12" fill="#c41e3a" font-weight="700" text-anchor="middle">Phase 2</text>
                            <text x="320" y="56" font-size="10" fill="#333" text-anchor="middle">Clinical Trials</text>
                            <text x="320" y="70" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ IDE Approval</text>
                            <text x="320" y="82" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ Patient Enrollment</text>
                            <text x="320" y="94" font-size="9" fill="#666" text-anchor="middle">6-12+ months</text>
                            
                            <path d="M 400 60 L 430 60" stroke="#c41e3a" stroke-width="2" marker-end="url(#arrow4)"/>
                            
                            <!-- Phase 3: PMA Submission -->
                            <rect x="430" y="20" width="160" height="80" rx="8" fill="#ffb3b3" opacity="0.3" stroke="#c41e3a" stroke-width="2"/>
                            <text x="510" y="40" font-size="12" fill="#c41e3a" font-weight="700" text-anchor="middle">Phase 3</text>
                            <text x="510" y="56" font-size="10" fill="#333" text-anchor="middle">PMA Submission</text>
                            <text x="510" y="70" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ Complete Data</text>
                            <text x="510" y="82" font-size="9" fill="#666" text-anchor="middle">‚Ä¢ Manufacturing Info</text>
                            <text x="510" y="94" font-size="9" fill="#666" text-anchor="middle">1-2 months prep</text>
                            
                            <path d="M 510 100 L 510 130" stroke="#c41e3a" stroke-width="2" marker-end="url(#arrow4)"/>
                            
                            <!-- Phase 4: FDA Review -->
                            <rect x="320" y="130" width="380" height="60" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="510" y="152" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">Phase 4: FDA Review & Advisory Panel</text>
                            <text x="510" y="168" font-size="9" fill="#333" text-anchor="middle">Filing review (45 days) ‚Üí Substantive review (180 days) ‚Üí Advisory panel meeting</text>
                            <text x="510" y="182" font-size="9" fill="#666" font-weight="600" text-anchor="middle">6-12 months review time</text>
                            
                            <path d="M 510 190 L 510 215" stroke="#c41e3a" stroke-width="2" marker-end="url(#arrow4)"/>
                            
                            <!-- Phase 5: Approval -->
                            <rect x="380" y="215" width="260" height="50" rx="8" fill="#90ee90" opacity="0.4" stroke="#2d862d" stroke-width="2"/>
                            <text x="510" y="237" font-size="13" fill="#2d862d" font-weight="700" text-anchor="middle">PMA Approval ‚Üí Market Entry</text>
                            <text x="510" y="253" font-size="10" fill="#333" text-anchor="middle">Post-Approval Studies &amp; Surveillance Required</text>
                            
                            <!-- Timeline indicator -->
                            <rect x="50" y="130" width="200" height="50" rx="8" fill="#fff9e6" stroke="#ffd700" stroke-width="2"/>
                            <text x="150" y="148" font-size="11" fill="#b8860b" font-weight="700" text-anchor="middle">Total Timeline</text>
                            <text x="150" y="163" font-size="13" fill="#c41e3a" font-weight="700" text-anchor="middle">12-18+ Months</text>
                            <text x="150" y="176" font-size="9" fill="#666" text-anchor="middle">(Can extend to 2-3 years)</text>
                            
                            <defs>
                                <marker id="arrow4" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                    <polygon points="0 0, 10 3, 0 6" fill="#c41e3a" />
                                </marker>
                            </defs>
                        </svg>
                        <p class="diagram-label">PMA Approval Process Timeline</p>
                    </div>

                    <div class="example-box">
                        <div class="example-title">
                            <span class="example-icon">üí°</span>
                            Real-World Example: AI-Powered Stroke Detection System
                        </div>
                        <p class="example-text">
                            <strong>Device:</strong> Viz.ai Contact - AI system for rapid stroke detection and triage<br><br>
                            <strong>Function:</strong> Analyzes CT scans to detect large vessel occlusions (LVO) in suspected stroke patients, automatically notifying stroke teams for immediate intervention<br><br>
                            <strong>Why High-Risk?:</strong> Time-critical diagnosis affecting treatment decisions for life-threatening condition. Delayed or missed detection could result in severe disability or death.<br><br>
                            <strong>Clinical Evidence Required:</strong> Prospective multi-center clinical trials demonstrating diagnostic accuracy, sensitivity/specificity for LVO detection, and impact on treatment timelines<br><br>
                            <strong>Outcome:</strong> FDA granted De Novo classification (not PMA) after extensive clinical validation showed low-to-moderate risk with special controls. However, similar diagnostic AI systems for higher-risk autonomous decisions may require PMA.
                        </p>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚úì Critical PMA Success Factors:</div>
                        <ul class="detail-list">
                            <li>Early and frequent FDA pre-submission meetings</li>
                            <li>Robust clinical trial design with appropriate endpoints</li>
                            <li>Comprehensive risk mitigation strategies</li>
                            <li>Quality management systems compliant with 21 CFR 820</li>
                            <li>Substantial financial and time resources (typically $10M+ and 2-3 years)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- 4. SOFTWARE MODIFICATIONS -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">4</div>
                    <div class="detail-title">Software Modifications and Algorithm Changes</div>
                </div>
                
                <div class="detail-content">
                    <div class="timeline-badge">‚è± Variable Timeline: Depends on change type</div>
                    <span class="risk-badge risk-moderate">Continuous Evolution</span>
                    
                    <div class="detail-subsection">
                        <div class="subsection-title">The Challenge of AI/ML Algorithm Updates</div>
                        <p class="detail-text">
                            AI/ML medical devices present unique regulatory challenges because algorithms can learn and adapt over time. Traditional medical device regulations weren't designed for "locked" vs. "adaptive" algorithms. The FDA has developed new frameworks to enable safe and effective algorithm modifications while maintaining regulatory oversight.
                        </p>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Types of Software Changes:</div>
                        <ul class="detail-list">
                            <li><strong>Minor Changes (No New Submission):</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>Bug fixes that don't affect performance</li>
                                    <li>User interface improvements</li>
                                    <li>Performance optimizations within validated parameters</li>
                                    <li>Security patches</li>
                                </ul>
                            </li>
                            <li><strong>Moderate Changes (May Require Notification):</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>Algorithm retraining on new data within predetermined specifications</li>
                                    <li>Performance improvements within established bounds</li>
                                    <li>Changes to input data specifications</li>
                                </ul>
                            </li>
                            <li><strong>Major Changes (New Submission Required):</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>Changes to intended use or indications</li>
                                    <li>Modifications affecting fundamental algorithm architecture</li>
                                    <li>New clinical applications</li>
                                    <li>Changes that could significantly affect safety or effectiveness</li>
                                </ul>
                            </li>
                        </ul>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Predetermined Change Control Plans (PCCP)</div>
                        <p class="detail-text">
                            The FDA's action plan for AI/ML-based Software as a Medical Device (SaMD) introduces the concept of Predetermined Change Control Plans. This allows manufacturers to specify in advance what types of modifications they plan to make and how they will manage those changes safely.
                        </p>
                    </div>

                    <div class="visual-diagram">
                        <svg width="800" height="320" viewBox="0 0 800 320">
                            <!-- Center: Algorithm -->
                            <ellipse cx="400" cy="160" rx="100" ry="60" fill="#1E64C8" opacity="0.8"/>
                            <text x="400" y="155" font-size="13" fill="white" font-weight="700" text-anchor="middle">AI/ML</text>
                            <text x="400" y="172" font-size="13" fill="white" font-weight="700" text-anchor="middle">Algorithm</text>
                            
                            <!-- Minor Changes (Top) -->
                            <rect x="320" y="20" width="160" height="70" rx="8" fill="#90ee90" opacity="0.5" stroke="#2d862d" stroke-width="2"/>
                            <text x="400" y="40" font-size="11" fill="#2d862d" font-weight="700" text-anchor="middle">Minor Changes</text>
                            <text x="400" y="54" font-size="9" fill="#333" text-anchor="middle">No FDA Submission</text>
                            <text x="400" y="66" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Bug fixes</text>
                            <text x="400" y="77" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ UI improvements</text>
                            <text x="400" y="88" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Security patches</text>
                            
                            <path d="M 400 90 L 400 100" stroke="#2d862d" stroke-width="2" stroke-dasharray="3,3" marker-end="url(#arrow5)"/>
                            
                            <!-- Moderate Changes (Left) -->
                            <rect x="50" y="120" width="180" height="80" rx="8" fill="#ffd700" opacity="0.4" stroke="#b8860b" stroke-width="2"/>
                            <text x="140" y="138" font-size="11" fill="#b8860b" font-weight="700" text-anchor="middle">Moderate Changes</text>
                            <text x="140" y="152" font-size="9" fill="#333" text-anchor="middle">PCCP or 510(k) Letter</text>
                            <text x="140" y="165" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Retraining on new data</text>
                            <text x="140" y="176" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Performance tweaks</text>
                            <text x="140" y="187" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Input specification changes</text>
                            <text x="140" y="198" font-size="8" fill="#666" text-anchor="middle">within preset bounds</text>
                            
                            <path d="M 230 160 L 300 160" stroke="#b8860b" stroke-width="2" stroke-dasharray="3,3" marker-end="url(#arrow5)"/>
                            
                            <!-- Major Changes (Right) -->
                            <rect x="570" y="120" width="180" height="80" rx="8" fill="#ffb3b3" opacity="0.4" stroke="#c41e3a" stroke-width="2"/>
                            <text x="660" y="138" font-size="11" fill="#c41e3a" font-weight="700" text-anchor="middle">Major Changes</text>
                            <text x="660" y="152" font-size="9" fill="#333" text-anchor="middle">New 510(k) Required</text>
                            <text x="660" y="165" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ New intended use</text>
                            <text x="660" y="176" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Architecture changes</text>
                            <text x="660" y="187" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ New clinical applications</text>
                            <text x="660" y="198" font-size="8" fill="#666" text-anchor="middle">‚Ä¢ Safety/effectiveness impact</text>
                            
                            <path d="M 500 160 L 570 160" stroke="#c41e3a" stroke-width="2" stroke-dasharray="3,3" marker-end="url(#arrow5)"/>
                            
                            <!-- PCCP Framework (Bottom) -->
                            <rect x="200" y="240" width="400" height="70" rx="8" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="400" y="260" font-size="12" fill="#1E64C8" font-weight="700" text-anchor="middle">Predetermined Change Control Plan (PCCP)</text>
                            <text x="400" y="275" font-size="9" fill="#333" text-anchor="middle">Specifies in advance: (1) Modification types (2) Methodology for implementing</text>
                            <text x="400" y="288" font-size="9" fill="#333" text-anchor="middle">changes (3) Impact assessment approach (4) Risk management procedures</text>
                            <text x="400" y="301" font-size="9" fill="#666" font-style="italic" text-anchor="middle">Enables continuous improvement while maintaining FDA oversight</text>
                            
                            <path d="M 400 220 L 400 240" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow5)"/>
                            
                            <defs>
                                <marker id="arrow5" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                    <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                                </marker>
                            </defs>
                        </svg>
                        <p class="diagram-label">Software Modification Decision Framework</p>
                    </div>

                    <div class="example-box">
                        <div class="example-title">
                            <span class="example-icon">üí°</span>
                            Real-World Example: Continuous Learning in Radiology AI
                        </div>
                        <p class="example-text">
                            <strong>Scenario:</strong> An FDA-cleared AI system for detecting lung nodules in chest X-rays<br><br>
                            <strong>Minor Update (No submission):</strong> Fixed a bug causing occasional crashes when processing certain image formats. Improved user interface for radiologists to review findings more efficiently.<br><br>
                            <strong>Moderate Update (PCCP):</strong> Retrained the algorithm on 50,000 additional chest X-rays to improve detection of subtle nodules. Performance improved from 92% to 94% sensitivity, within the bounds specified in the original PCCP. Manufacturer documented changes and notified FDA per predetermined protocol.<br><br>
                            <strong>Major Update (New 510(k)):</strong> Expanded the algorithm to detect pneumonia in addition to lung nodules. This represents a new intended use and required a new 510(k) submission with clinical validation for the pneumonia detection capability.
                        </p>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚úì Best Practices for Managing Algorithm Changes:</div>
                        <ul class="detail-list">
                            <li>Develop comprehensive PCCP during initial submission</li>
                            <li>Maintain detailed change logs and version control</li>
                            <li>Establish clear performance boundaries and validation metrics</li>
                            <li>Implement robust monitoring systems to detect performance drift</li>
                            <li>Consult with FDA early if uncertain about modification classification</li>
                            <li>Document all changes thoroughly, even minor ones</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- 5. POST-MARKET SURVEILLANCE -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">5</div>
                    <div class="detail-title">Post-Market Surveillance and Real-World Performance</div>
                </div>
                
                <div class="detail-content">
                    <div class="timeline-badge">‚è± Ongoing: Throughout device lifecycle</div>
                    <span class="risk-badge risk-moderate">Mandatory Monitoring</span>
                    
                    <div class="detail-subsection">
                        <div class="subsection-title">Why Post-Market Surveillance Matters for AI/ML</div>
                        <p class="detail-text">
                            Post-market surveillance is especially critical for AI/ML medical devices because their performance in real-world settings may differ from controlled clinical trials. Algorithm performance can drift due to changes in patient populations, clinical workflows, or data quality. Continuous monitoring ensures devices maintain safety and effectiveness throughout their lifecycle.
                        </p>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Required Surveillance Activities:</div>
                        <ul class="detail-list">
                            <li><strong>Medical Device Reporting (MDR):</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>Report deaths within 30 days</li>
                                    <li>Report serious injuries within 30 days</li>
                                    <li>Report malfunctions within 30 days (for Class III)</li>
                                    <li>Maintain complaint files and investigation records</li>
                                </ul>
                            </li>
                            <li><strong>Performance Monitoring:</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>Track diagnostic accuracy metrics (sensitivity, specificity, PPV, NPV)</li>
                                    <li>Monitor for performance drift across patient subpopulations</li>
                                    <li>Analyze false positive and false negative rates</li>
                                    <li>Assess clinical utility and user experience</li>
                                </ul>
                            </li>
                            <li><strong>Post-Approval Studies:</strong>
                                <ul style="margin-left: 20px; margin-top: 5px;">
                                    <li>May be required as condition of PMA approval</li>
                                    <li>Long-term effectiveness studies</li>
                                    <li>Real-world evidence generation</li>
                                </ul>
                            </li>
                        </ul>
                    </div>

                    <div class="detail-subsection">
                        <div class="subsection-title">Performance Drift Detection</div>
                        <p class="detail-text">
                            AI algorithms may experience performance degradation when deployed in real-world settings due to distribution shift, where the data encountered differs from training data. Manufacturers must implement systems to detect and respond to performance drift.
                        </p>
                    </div>

                    <div class="visual-diagram">
                        <svg width="800" height="350" viewBox="0 0 800 350">
                            <!-- Timeline -->
                            <line x1="50" y1="60" x2="750" y2="60" stroke="#1E64C8" stroke-width="3"/>
                            
                            <!-- Market Entry -->
                            <circle cx="100" cy="60" r="15" fill="#90ee90" stroke="#2d862d" stroke-width="2"/>
                            <text x="100" y="65" font-size="10" fill="#2d862d" font-weight="700" text-anchor="middle">‚úì</text>
                            <text x="100" y="90" font-size="11" fill="#2d862d" font-weight="700" text-anchor="middle">Market</text>
                            <text x="100" y="103" font-size="11" fill="#2d862d" font-weight="700" text-anchor="middle">Entry</text>
                            
                            <!-- Continuous Monitoring Points -->
                            <circle cx="250" cy="60" r="12" fill="#1E64C8" opacity="0.7"/>
                            <circle cx="400" cy="60" r="12" fill="#1E64C8" opacity="0.7"/>
                            <circle cx="550" cy="60" r="12" fill="#1E64C8" opacity="0.7"/>
                            <circle cx="700" cy="60" r="12" fill="#1E64C8" opacity="0.7"/>
                            
                            <text x="250" y="85" font-size="9" fill="#1E64C8" text-anchor="middle">Month 3</text>
                            <text x="400" y="85" font-size="9" fill="#1E64C8" text-anchor="middle">Month 6</text>
                            <text x="550" y="85" font-size="9" fill="#1E64C8" text-anchor="middle">Month 12</text>
                            <text x="700" y="85" font-size="9" fill="#1E64C8" text-anchor="middle">Ongoing</text>
                            
                            <!-- Surveillance Activities -->
                            <rect x="50" y="130" width="340" height="200" rx="8" fill="#f8fbff" stroke="#1E64C8" stroke-width="2"/>
                            <text x="220" y="152" font-size="13" fill="#1E64C8" font-weight="700" text-anchor="middle">Surveillance Activities</text>
                            
                            <!-- Activity 1 -->
                            <rect x="70" y="165" width="140" height="45" rx="6" fill="white" stroke="#1E64C8" stroke-width="1.5"/>
                            <text x="140" y="180" font-size="10" fill="#1E64C8" font-weight="700" text-anchor="middle">MDR Reporting</text>
                            <text x="140" y="193" font-size="8" fill="#666" text-anchor="middle">Deaths, injuries,</text>
                            <text x="140" y="204" font-size="8" fill="#666" text-anchor="middle">malfunctions</text>
                            
                            <!-- Activity 2 -->
                            <rect x="230" y="165" width="140" height="45" rx="6" fill="white" stroke="#1E64C8" stroke-width="1.5"/>
                            <text x="300" y="180" font-size="10" fill="#1E64C8" font-weight="700" text-anchor="middle">Performance Metrics</text>
                            <text x="300" y="193" font-size="8" fill="#666" text-anchor="middle">Accuracy, drift,</text>
                            <text x="300" y="204" font-size="8" fill="#666" text-anchor="middle">subgroup analysis</text>
                            
                            <!-- Activity 3 -->
                            <rect x="70" y="220" width="140" height="45" rx="6" fill="white" stroke="#1E64C8" stroke-width="1.5"/>
                            <text x="140" y="235" font-size="10" fill="#1E64C8" font-weight="700" text-anchor="middle">User Feedback</text>
                            <text x="140" y="248" font-size="8" fill="#666" text-anchor="middle">Usability issues,</text>
                            <text x="140" y="259" font-size="8" fill="#666" text-anchor="middle">workflow integration</text>
                            
                            <!-- Activity 4 -->
                            <rect x="230" y="220" width="140" height="45" rx="6" fill="white" stroke="#1E64C8" stroke-width="1.5"/>
                            <text x="300" y="235" font-size="10" fill="#1E64C8" font-weight="700" text-anchor="middle">Complaint Handling</text>
                            <text x="300" y="248" font-size="8" fill="#666" text-anchor="middle">Investigation,</text>
                            <text x="300" y="259" font-size="8" fill="#666" text-anchor="middle">root cause analysis</text>
                            
                            <!-- Activity 5 -->
                            <rect x="70" y="275" width="300" height="45" rx="6" fill="white" stroke="#1E64C8" stroke-width="1.5"/>
                            <text x="220" y="290" font-size="10" fill="#1E64C8" font-weight="700" text-anchor="middle">Post-Approval Studies (if required)</text>
                            <text x="220" y="303" font-size="8" fill="#666" text-anchor="middle">Long-term effectiveness, real-world evidence,</text>
                            <text x="220" y="314" font-size="8" fill="#666" text-anchor="middle">comparative studies</text>
                            
                            <!-- Response Actions -->
                            <rect x="420" y="130" width="340" height="200" rx="8" fill="#fff9e6" stroke="#ffd700" stroke-width="2"/>
                            <text x="590" y="152" font-size="13" fill="#b8860b" font-weight="700" text-anchor="middle">Response Actions</text>
                            
                            <!-- Action 1 -->
                            <rect x="440" y="165" width="140" height="45" rx="6" fill="white" stroke="#ffd700" stroke-width="1.5"/>
                            <text x="510" y="180" font-size="10" fill="#b8860b" font-weight="700" text-anchor="middle">Algorithm Update</text>
                            <text x="510" y="193" font-size="8" fill="#666" text-anchor="middle">Retrain, modify</text>
                            <text x="510" y="204" font-size="8" fill="#666" text-anchor="middle">per PCCP</text>
                            
                            <!-- Action 2 -->
                            <rect x="600" y="165" width="140" height="45" rx="6" fill="white" stroke="#ffd700" stroke-width="1.5"/>
                            <text x="670" y="180" font-size="10" fill="#b8860b" font-weight="700" text-anchor="middle">Label Update</text>
                            <text x="670" y="193" font-size="8" fill="#666" text-anchor="middle">Warnings,</text>
                            <text x="670" y="204" font-size="8" fill="#666" text-anchor="middle">contraindications</text>
                            
                            <!-- Action 3 -->
                            <rect x="440" y="220" width="140" height="45" rx="6" fill="white" stroke="#ffd700" stroke-width="1.5"/>
                            <text x="510" y="235" font-size="10" fill="#b8860b" font-weight="700" text-anchor="middle">Field Action</text>
                            <text x="510" y="248" font-size="8" fill="#666" text-anchor="middle">Safety notice,</text>
                            <text x="510" y="259" font-size="8" fill="#666" text-anchor="middle">device removal</text>
                            
                            <!-- Action 4 -->
                            <rect x="600" y="220" width="140" height="45" rx="6" fill="white" stroke="#ffd700" stroke-width="1.5"/>
                            <text x="670" y="235" font-size="10" fill="#b8860b" font-weight="700" text-anchor="middle">FDA Notification</text>
                            <text x="670" y="248" font-size="8" fill="#666" text-anchor="middle">Report issues,</text>
                            <text x="670" y="259" font-size="8" fill="#666" text-anchor="middle">seek guidance</text>
                            
                            <!-- Action 5 -->
                            <rect x="440" y="275" width="300" height="45" rx="6" fill="white" stroke="#ffd700" stroke-width="1.5"/>
                            <text x="590" y="290" font-size="10" fill="#b8860b" font-weight="700" text-anchor="middle">Recall (if necessary)</text>
                            <text x="590" y="303" font-size="8" fill="#666" text-anchor="middle">Class I/II/III recall based on risk severity</text>
                            <text x="590" y="314" font-size="8" fill="#666" text-anchor="middle">Correction, removal, or market withdrawal</text>
                        </svg>
                        <p class="diagram-label">Post-Market Surveillance Lifecycle</p>
                    </div>

                    <div class="example-box">
                        <div class="example-title">
                            <span class="example-icon">üí°</span>
                            Real-World Example: Performance Drift in AI ECG Interpretation
                        </div>
                        <p class="example-text">
                            <strong>Scenario:</strong> An FDA-cleared AI system for detecting atrial fibrillation (AFib) in ECG signals<br><br>
                            <strong>Initial Performance:</strong> In clinical trials: 98% sensitivity, 95% specificity for AFib detection<br><br>
                            <strong>Post-Market Monitoring Findings (6 months):</strong>
                            ‚Ä¢ Overall performance maintained: 97.5% sensitivity, 94.8% specificity
                            ‚Ä¢ Performance drift detected in elderly patients (>80 years): sensitivity dropped to 92%
                            ‚Ä¢ Higher false positive rate in patients with pacemakers (12% vs. 5% in trials)<br><br>
                            <strong>Manufacturer Response:</strong>
                            1. Collected additional data from affected populations
                            2. Retrained algorithm using augmented dataset per PCCP
                            3. Updated labeling to include specific performance metrics for elderly patients and pacemaker users
                            4. Notified FDA of modifications through predetermined change control process
                            5. Implemented enhanced monitoring for these subgroups<br><br>
                            <strong>Outcome:</strong> Updated algorithm achieved 96% sensitivity in elderly patients. Added clinical decision support features to alert users when accuracy may be affected by patient factors.
                        </p>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚úì Best Practices for Post-Market Surveillance:</div>
                        <ul class="detail-list">
                            <li>Implement automated performance monitoring dashboards</li>
                            <li>Establish clear thresholds for performance metrics that trigger investigation</li>
                            <li>Analyze performance across diverse patient subpopulations</li>
                            <li>Maintain open communication channels with end users</li>
                            <li>Develop robust complaint handling and investigation procedures</li>
                            <li>Conduct regular internal audits of surveillance data</li>
                            <li>Stay proactive - address issues before they become serious safety concerns</li>
                            <li>Maintain detailed documentation of all surveillance activities and responses</li>
                        </ul>
                    </div>

                    <div class="key-points">
                        <div class="key-points-title">‚ö†Ô∏è Common Post-Market Issues for AI Devices:</div>
                        <ul class="detail-list">
                            <li><strong>Data Drift:</strong> Changes in patient population characteristics or data quality</li>
                            <li><strong>Integration Issues:</strong> Problems with EMR/EHR integration affecting data input</li>
                            <li><strong>Workflow Challenges:</strong> Devices not fitting seamlessly into clinical workflows</li>
                            <li><strong>User Error:</strong> Misinterpretation of AI outputs or recommendations</li>
                            <li><strong>Environmental Factors:</strong> Different imaging equipment, hospital settings affecting performance</li>
                            <li><strong>Adversarial Inputs:</strong> Unexpected data patterns causing incorrect outputs</li>
                        </ul>
                    </div>
                </div>
            </div>

        </div>

        <!-- Footer -->
        <div style="margin-top: 50px; padding-top: 20px; border-top: 2px solid #1E64C8; text-align: center;">
            <p style="font-size: 12px; color: #666; line-height: 1.6;">
                <strong>Important Note:</strong> This document provides educational information about FDA regulatory pathways for AI/ML medical devices. 
                Manufacturers should consult with FDA directly and seek qualified regulatory counsel for specific guidance on their devices. 
                Regulatory requirements and policies continue to evolve, especially for AI/ML technologies.
            </p>
            <p style="font-size: 11px; color: #999; margin-top: 10px;">
                For the latest FDA guidance, visit: <a href="https://www.fda.gov/medical-devices/software-medical-device-samd" style="color: #1E64C8;">www.fda.gov/medical-devices</a>
            </p>
        </div>
    </div>
</body>
</html>